Cannabis-Based Products for Chronic Pain: An Updated Systematic Review
The DOI matches its Crossref record, with a small difference in title or year; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services (PROSPERO: CRD42021229579).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Self-citationPrevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016
Dahlhamer, J., Lucas, J., Zelaya, Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., & Helmick, C. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6736a2 · Cited by 2,598
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Cannabis-based medicines for chronic neuropathic pain in adults
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182.pub2 · Cited by 571
A LIKELIHOOD APPROACH TO META-ANALYSIS WITH RANDOM EFFECTS
Hardy, R., & Thompson, S. G. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960330)15:6<671::aid-sim205>3.0.co;2-5 · Cited by 527
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_4 · Cited by 454
Blake, D. R., Robson, P., Ho, M., Jubb, R. W., & McCabe, C. S. (2006) · Rheumatology · doi:10.1093/rheumatology/kei183 · Cited by 433
Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007) · Pain · doi:10.1016/j.pain.2007.08.028 · Cited by 431
Nabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 376
Nugent, S. M., Morasco, B. J., O'Neil, M. E., Freeman, M., Low, A., Kondo, K., Elven, C., Zakher, B., Motu'apuaka, M., Paynter, R., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0155 · Cited by 301
Self-citationWang, L., Hong, P. J., May, C., Rehman, Y., Oparin, Y., Hong, C. J., Hong, B. Y., AminiLari, M., Gallo, L., Kaushal, A., et al. (2021) · BMJ · doi:10.1136/bmj.n1034 · Cited by 300
Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6739-4 · Cited by 298
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D., Mattison, P. G., & on behalf of the MUSEC Research Group (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302468 · Cited by 278
Lynch, M. E., Cesar-Rittenberg, P., & Hohmann, A. G. (2014) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2013.02.018 · Cited by 266
Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update
Skelly, A. C., Chou, R., Dettori, J. R., Turner, J. A., Friedly, J. L., Rundell, S. D., Fu, R., Brodt, E. D., Wasson, N., Kantner, S., et al. (2020) · doi:10.23970/ahrqepccer227 · Cited by 256
Self-citationCannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
Finn, D. P., Haroutounian, S., Hohmann, A. G., Krane, E., Soliman, N., & Rice, A. S. C. (2021) · Pain · doi:10.1097/j.pain.0000000000002268 · Cited by 254
Xu, D. H., Cullen, B. D., Tang, M., & Fang, Y. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666191202111534 · Cited by 206
Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., Lauder, H., & Ehler, E. (2014) · European Journal of Pain · doi:10.1002/j.1532-2149.2013.00445.x · Cited by 197
Selvarajah, D., Gandhi, R., Emery, C. J., & Tesfaye, S. (2010) · Diabetes Care · doi:10.2337/dc09-1029 · Cited by 189
Toth, C., Mawani, S., Brady, S., Chan, C., Liu, C., Mehina, E., Garven, A., Bestard, J., & Korngut, L. (2012) · Pain · doi:10.1016/j.pain.2012.06.024 · Cited by 174
Cannabis-Based Products for Chronic Pain: A Systematic Review
McDonagh, M. S., Morasco, B. J., Wagner, J., Ahmed, A. Y., Fu, R. F., Kansagara, D. L., & Chou, R. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4520 · Cited by 173
Self-citationWissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., & Schelosky, L. D. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0218-8 · Cited by 171
Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews
Cashin, A. G., Wand, B. M., O'Connell, N. E., Lee, H., Rizzo, R. R. N., Bagg, M. K., O’Hagan, E. T., Maher, C. G., Furlan, A. D., van Tulder, M. W., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013815.pub2 · Cited by 157
Opioid Treatments for Chronic Pain
Chou, R., Hartung, D., Turner, J., Blazina, I., Chan, B., Levander, X., McDonagh, M., Selph, S., Fu, R., & Pappas, M. (2020) · doi:10.23970/ahrqepccer229 · Cited by 152
Self-citationChaves, C., Trevisol-Bittencourt, P. C., & Pelegrini, A. (2020) · Pain Medicine · doi:10.1093/pm/pnaa303 · Cited by 143
The analgesic potential of cannabinoids.
Elikottil, M., Gupta, M., & Gupta, P. (2018) · Journal of Opioid Management · doi:10.5055/jom.2009.0034 · Cited by 141
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D. (2017) · European Neurology · doi:10.1159/000481089 · Cited by 136
Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., Galloway, K., & Namaka, M. (2015) · Pain Medicine · doi:10.1111/pme.12569 · Cited by 124
Vela, J., Dreyer, L., Petersen, K. K., Arendt‐Nielsen, L., Duch, K. S., & Kristensen, S. (2021) · Pain · doi:10.1097/j.pain.0000000000002466 · Cited by 123
Testing overall and moderator effects in random effects meta‐regression
Huizenga, H. M., Visser, I., & Dolan, C. V. (2011) · British Journal of Mathematical and Statistical Psychology · doi:10.1348/000711010x522687 · Cited by 100
de Vries, M., van Rijckevorsel, D. C., Vissers, K. C. P., Wilder‐Smith, O. H. G., & van Goor, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.09.147 · Cited by 100
Okusanya, B. O., Asaolu, I. O., Ehiri, J. E., Kimaru, L. J., Okechukwu, A., & Rosales, C. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01425-3 · Cited by 98
Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W. (2006) · Wiener klinische Wochenschrift · doi:10.1007/s00508-006-0611-4 · Cited by 96
Zeraatkar, D., Cooper, M. A., Agarwal, A., Vernooij, R. W. M., Leung, G., Loniewski, K., Dookie, J., Ahmed, M. M., Hong, B. Y., Hong, C. J. H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054282 · Cited by 96
Nonopioid Pharmacologic Treatments for Chronic Pain
McDonagh, M. S., Selph, S., Buckley, D., Holmes, R. S., Mauer, K. M., Ramirez, S., Hsu, F. C., Dana, T., Fu, R., & Chou, R. (2020) · doi:10.23970/ahrqepccer228 · Cited by 93
Self-citationConfidence intervals for a random‐effects meta‐analysis based on Bartlett‐type corrections
Noma, H. (2011) · Statistics in Medicine · doi:10.1002/sim.4350 · Cited by 82
Safety and Efficacy of Medicinal Cannabis in the Treatment of Fibromyalgia: A Systematic Review
Kurlyandchik, I., Tiralongo, E., & Schloss, J. M. (2020) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2020.0331 · Cited by 60
Barakji, J. A., Korang, S. K., Feinberg, J. B., Maagaard, M., Mathiesen, O., Gluud, C. N., & Jakobsen, J. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0267420 · Cited by 54
Zubcevic, K., Petersen, M., Bach, F. W., Heinesen, A., Enggaard, T. P., Almdal, T., Holbech, J. V., Vase, L., Jensen, T. S., Hansen, C. S., et al. (2022) · European Journal of Pain · doi:10.1002/ejp.2072 · Cited by 50
Wong, S., Chan, W.-S., & Cheung, C. W. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09905-y · Cited by 48
Cannabidivarin for HIV‐Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial
Eibach, L., Scheffel, S., Cardebring, M., Lettau, M., Celik, M. Ö., Morguet, A. J., Roehle, R., & Stein, C. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2016 · Cited by 47
Hansen, J. S., Gustavsen, S., Roshanisefat, H., Kant, M., Biering‐Sørensen, F., Andersen, C. Y., Olsson, A., Chow, H. H., Asgari, N., Hansen, J. R., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081079 · Cited by 41
Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials
Longo, R., Oudshoorn, A., & Befus, D. (2021) · Pain Management Nursing · doi:10.1016/j.pmn.2020.11.006 · Cited by 39
Pramhas, S., Thalhammer, T., Terner, S., Pickelsberger, D., Gleiß, A., Sator, S., & Kress, H. G. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100777 · Cited by 38
Walczyńska-Dragon, K., Kurek-Górecka, A., Niemczyk, W., Nowak, Z., Baron, S., Olczyk, P., Nitecka-Buchta, A., & Kempa, W. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051417 · Cited by 36
Lile, J. A., Kelly, T. H., & Hays, L. R. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181e77428 · Cited by 31
Medical marijuana and pain management
Temple, L. M. (2016) · Disease-a-Month · doi:10.1016/j.disamonth.2016.05.014 · Cited by 30
Hansen, J. S., Boix, F., Hasselstrøm, J. B., Sørensen, L. K., Kjølby, M., Gustavsen, S., Hansen, R. M., Petersen, T., Sellebjerg, F. T., Kasch, H., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13685 · Cited by 27
Rittiphairoj, T., Leslie, L., Oberste, J.-P., Yim, T. W., Tung, G. J., Bero, L. A., Riggs, P., Hutchison, K. E., Samet, J. M., & Li, T. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03819 · Cited by 25
Seevathee, K., Kessomboon, P., Manimmanakorn, N., Luangphimai, S., Thaneerat, T., Wanaratna, K., Plengphanich, S., Thaenkham, T., & Sena, W. (2024) · Medical Cannabis and Cannabinoids · doi:10.1159/000542511 · Cited by 12
Abbasifard, M., Moosavi, Z., Azimi, M., Kamiab, Z., Bazmandegan, G., Madahian, A. M., & Raeiszadeh, M. (2024) · Pain Management Nursing · doi:10.1016/j.pmn.2024.08.001 · Cited by 9
Bassat, O. K., Schechter, M., Ashtamker, N., Yanuv, I., Rozenberg, A., Hirshberg, B., Grupper, A., Vaisman, N., Brill, S., & Mosenzon, O. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac275 · Cited by 6
Cited by
Cooper, Z. D. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-04734
Hernandez‐Vallant, A., Kaskie, B. P., & Bobitt, J. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2662699
“…suggest that sub-stituting cannabis for opioids may reduce opioid use, medication side effects, and certain health risks 17–20 , more recent systematic reviews suggests that cannabis use may improve chronic pain in the short term while increasing side effects such as dizziness and sedation 21,22 .”
Odonkor, C. A., Karpe, D. A., Siddique, M. U., & Abd-Elsayed, A. A. (2026) · Pharmaceuticals · doi:10.3390/ph19081151 · Cited by 1
“…review and serial Annals of Internal Medicine syntheses, indicate that cannabis-based medicines—most consistently the THC: CBD oromucosal spray nabiximols—produce a small improvement in pain, on the order of 0.5–1.0 points on a 0–10 scale, corresponding to a small, standardized effect [53–55].”
InfluentialNeves, L. B. M., Daniel Domingues dos, S., Baldessarini, B. L., Laino, P. H., Neto, M. P. C., & Lima, B. C. (2026) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2026.08.007
Metadata
- Authors
- Chou, R., Fu, R., Ahmed, A. Y., & Morasco, B. J.
- Affiliations
- Oregon Health & Science University (US)
- Portland State University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2026-02
- Volume
- 179
- Issue
- 2
- Pages
- 230-241
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W7116922717
- Cited by
- 4
- References
- 53
- Citations by year
- 2026: 3
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- cannabinoids, chronic pain, neuropathic pain, tetrahydrocannabinol, cannabidiol, nabilone, dronabinol, adverse events, sedation, nausea, pain intensity
- MeSH terms
- Cannabidiol, Cannabinoids, Humans, Dronabinol, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.